These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 36372815

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. A link between the intrarenal renin angiotensin system and hypertension in autosomal dominant polycystic kidney disease.
    Kocyigit I, Yilmaz MI, Unal A, Ozturk F, Eroglu E, Yazici C, Orscelik O, Sipahioglu MH, Tokgoz B, Oymak O.
    Am J Nephrol; 2013; 38(3):218-25. PubMed ID: 23988725
    [Abstract] [Full Text] [Related]

  • 23. Hyperaldosteronism and cardiovascular risk in patients with autosomal dominant polycystic kidney disease.
    Lai S, Petramala L, Mastroluca D, Petraglia E, Di Gaeta A, Indino E, Panebianco V, Ciccariello M, Shahabadi HH, Galani A, Letizia C, D'Angelo AR.
    Medicine (Baltimore); 2016 Jul; 95(29):e4175. PubMed ID: 27442639
    [Abstract] [Full Text] [Related]

  • 24. Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease.
    Nowak KL, Cadnapaphornchai MA, Chonchol MB, Schrier RW, Gitomer B.
    Am J Nephrol; 2016 Jul; 44(3):171-8. PubMed ID: 27548646
    [Abstract] [Full Text] [Related]

  • 25. Effect of 12-month nasal continuous positive airway pressure therapy for obstructive sleep apnea on progression of chronic kidney disease.
    Li X, Liu C, Zhang H, Zhang J, Zhao M, Sun D, Xia M, Han M.
    Medicine (Baltimore); 2019 Feb; 98(8):e14545. PubMed ID: 30813163
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Clinical presentation of obstructive sleep apnea in patients with chronic kidney disease.
    Nicholl DD, Ahmed SB, Loewen AH, Hemmelgarn BR, Sola DY, Beecroft JM, Turin TC, Hanly PJ.
    J Clin Sleep Med; 2012 Aug 15; 8(4):381-7. PubMed ID: 22893768
    [Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA, Whitmire S, Patton S, Clark C, Blanchette CM, Howden R.
    J Med Econ; 2017 Jul 15; 20(7):715-722. PubMed ID: 28332417
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Dysmetabolic markers predict outcomes in autosomal dominant polycystic kidney disease.
    Kocyigit I, Ozturk F, Eroglu E, Karaca Z, Kaynar AS, Cetin M, Tokgoz B, Sipahioglu MH, Bayramov R, Sen A, Oymak O, Ecder T, Axelsson J.
    Clin Exp Nephrol; 2019 Sep 15; 23(9):1130-1140. PubMed ID: 31134465
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Autosomal dominant polycystic kidney disease: role of the renin-angiotensin system in raised blood pressure in progression of renal and cardiovascular disease.
    Lawson CR, Doulton TW, MacGregor GA.
    J Renin Angiotensin Aldosterone Syst; 2006 Sep 15; 7(3):139-45. PubMed ID: 17094050
    [Abstract] [Full Text] [Related]

  • 34. Urinary citrate as a marker of renal function in patients with autosomal dominant polycystic kidney disease.
    Borrego Utiel FJ, Herrera Contreras I, Merino García E, Camacho Reina MV, Moriana Domínguez C, Ocaña Pérez E.
    Int Urol Nephrol; 2022 Apr 15; 54(4):873-881. PubMed ID: 34279821
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
    Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, Kenney PJ, King BF, Glockner JF, Wetzel LH, Brummer ME, O'Neill WC, Robbin ML, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort.
    Kidney Int; 2003 Sep 15; 64(3):1035-45. PubMed ID: 12911554
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
    Nakajima A, Lu Y, Kawano H, Horie S, Muto S.
    Clin Exp Nephrol; 2015 Dec 15; 19(6):1199-205. PubMed ID: 25715868
    [Abstract] [Full Text] [Related]

  • 40. Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study.
    Girardat-Rotar L, Puhan MA, Braun J, Serra AL.
    J Nephrol; 2018 Feb 15; 31(1):87-94. PubMed ID: 28386880
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.